Evidence map›Paper›PMID 40835839›Full record

ArticleNPJ vaccines2025

Immunofocusing on the conserved fusion peptide of HIV envelope glycoprotein in rhesus macaques.

Payal P Pratap, Christopher A Cottrell, James Quinn, Diane G Carnathan, Daniel L V Bader, Andy S Tran, Chiamaka A Enemuo, Julia T Ngo, Sara T Richey, Hongmei Gao and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Payal P PratapDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Christopher A CottrellCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
James QuinnCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Diane G CarnathanDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Daniel L V BaderDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Andy S TranDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Chiamaka A EnemuoDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Julia T NgoDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Sara T RicheyDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Hongmei GaoDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Xiaoying ShenDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Kelli M GreeneDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Jonathan HurtadoCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Katarzyna Kaczmarek MichaelsKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Elana Ben-AkivaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Ashley LemniosDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Mariane B MeloCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Joel D AllenSchool of Biological Sciences, University of Southampton, Southampton, UK.
Gabriel OzorowskiDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Max CrispinSchool of Biological Sciences, University of Southampton, Southampton, UK.
Bryan BrineyCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
David MontefioriDuke Human Vaccine Institute and Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Guido SilvestriDivision of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA, USA.
Darrell J IrvineCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Shane CrottyCenter for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, CA, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA. andrew@scripps.edu.

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Dissecting Polyclonal Sera to Reveal Correlates of Productive Immune Responses to HIVR01AI136621 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Lars Oliver Hangartner, Andrew Barrett Ward · 2018 to 2026
$8.0M
Fusion peptide directed immunogens that elicit neutralizing and protective antibodies in non-human primatesR01AI145629 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CROTTY, SHANE P, WARD, ANDREW BARRETT · 2019 to 2024
$4.5M
National Institute of Allergy and Infectious Diseases AI145629NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI136621NIAID NIH HHS R01 AI145629NIAID NIH HHS UM1 AI144462NIH HHS P51 OD011132Yerkes National Primate Research Center, Emory University P51OD011132
6 · The paper itself

Abstract

During infection, the fusion peptide (FP) of HIV envelope glycoprotein (Env) serves a central role in viral fusion with the host cell. As such, the FP is highly conserved and therefore an attractive epitope for vaccine design. Here, we describe a vaccination study in non-human primates (NHPs) where glycan deletions were made on soluble HIV Env to increase FP epitope exposure. When delivered via implantable osmotic pumps, this immunogen primed immune responses against the FP, which were then boosted with heterologous trimers resulting in a focused immune response targeting the conserved FP epitope. Although autologous immunizations did not elicit high affinity FP-targeting antibodies, the conserved FP epitope on a heterologous trimer further matured the lower affinity, FP-targeting B cells. This study suggests using epitope conservation strategies on distinct Env trimer immunogens can focus humoral responses on desired neutralizing epitopes and suppress immune-distracting antibody responses against non-neutralizing epitopes.

Identifiers

PMID40835839
PMCPMC12368129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.